Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simple vs six-branches autologous suburethral sling during robot-assisted radical prostatectomy to improve early urinary continence recovery: prospective randomized study.
Cestari A, Ferrari M, Sangalli M, Zanoni M, Ghezzi M, Fabbri F, Sozzi F, Lolli C, Dell'Acqua V, Rigatti P. Cestari A, et al. Among authors: lolli c. J Robot Surg. 2017 Dec;11(4):415-421. doi: 10.1007/s11701-017-0672-6. Epub 2017 Jan 11. J Robot Surg. 2017. PMID: 28078523 Clinical Trial.
Retropubic Intracorporeal Placement of a Suburethral Autologous Sling During Robot-Assisted Radical Prostatectomy to Improve Early Urinary Continence Recovery: Preliminary Data.
Cestari A, Ferrari M, Ghezzi M, Sangalli M, Zanoni M, Fabbri F, Sozzi F, Lolli C, Dell'Acqua V, Rigatti P. Cestari A, et al. Among authors: lolli c. J Endourol. 2015 Dec;29(12):1379-85. doi: 10.1089/end.2015.0292. Epub 2015 Sep 8. J Endourol. 2015. PMID: 26131781 Clinical Trial.
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.
Corianò M, Lazzarin A, Maffezzoli M, Santoni M, Mazzaschi G, Rodella S, Simoni N, Lai E, Maruzzo M, Basso U, Bimbatti D, Iacovelli R, Anghelone A, Fiala O, Rebuzzi SE, Fornarini G, Lolli C, Massari F, Rosellini M, Mollica V, Nasso C, Acunzo A, Silini EM, Quaini F, De Filippo M, Brunelli M, Banna GL, Rescigno P, Signori A, Buti S. Corianò M, et al. Among authors: lolli c. Immunotherapy. 2025 Jan 20:1-11. doi: 10.1080/1750743X.2025.2452145. Online ahead of print. Immunotherapy. 2025. PMID: 39829377
An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Serra R, Giunta EF, Schepisi G, Brighi N, Montanari D, Lolli C, Bleve S, Piras M, Palmieri G, Scartozzi M, Paliogiannis P, De Giorgi U. Serra R, et al. Among authors: lolli c. Expert Rev Anticancer Ther. 2024 Dec;24(12):1221-1227. doi: 10.1080/14737140.2024.2445152. Epub 2024 Dec 25. Expert Rev Anticancer Ther. 2024. PMID: 39716888 Review.
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.
Giunta EF, Caroli P, Scarpi E, Altavilla A, Rossetti V, Marini I, Celli M, Casadei C, Lolli C, Schepisi G, Bleve S, Brighi N, Cursano MC, Paganelli G, Matteucci F, De Giorgi U. Giunta EF, et al. Among authors: lolli c. Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):326-334. doi: 10.1007/s00259-024-06887-4. Epub 2024 Aug 29. Eur J Nucl Med Mol Imaging. 2024. PMID: 39207484 Free PMC article.
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
Massari F, Mollica V, Fiala O, De Giorgi U, Kucharz J, Vitale MG, Molina-Cerrillo J, Facchini G, Seront E, Lenci E, Bourlon MT, Carrozza F, Pichler R, Lolli C, Myint ZW, Kanesvaran R, Torniai M, Rescigno P, Gomez de Liaño A, Zakopoulou R, Buti S, Porta C, Grande E, Santoni M. Massari F, et al. Among authors: lolli c. Eur Urol Oncol. 2024 Oct;7(5):1123-1131. doi: 10.1016/j.euo.2024.03.011. Epub 2024 Apr 4. Eur Urol Oncol. 2024. PMID: 38575409
124 results